These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22333201)

  • 1. [Effects of donepezil treatment on platelets α and β secretase activities in Alzheimer's disease patients].
    Dong GS; Li X; Jiang QH; Yang HQ
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(47):3341-5. PubMed ID: 22333201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets.
    Sarno TA; Talib LL; Joaquim HP; Bram JM; Gattaz WF; Forlenza OV
    J Alzheimers Dis; 2017; 55(4):1445-1451. PubMed ID: 27858713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.
    Talib LL; Hototian SR; Joaquim HP; Forlenza OV; Gattaz WF
    Eur Arch Psychiatry Clin Neurosci; 2015 Dec; 265(8):701-6. PubMed ID: 25920742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
    Wilcock G; Howe I; Coles H; Lilienfeld S; Truyen L; Zhu Y; Bullock R; Kershaw P;
    Drugs Aging; 2003; 20(10):777-89. PubMed ID: 12875613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
    Rockwood K; Fay S; Gorman M; Carver D; Graham JE
    BMC Neurol; 2007 Aug; 7():26. PubMed ID: 17760991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
    Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
    J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD).
    Giordano M; Dominguez LJ; Vitrano T; Curatolo M; Ferlisi A; Di Prima A; Belvedere M; Barbagallo M
    Arch Gerontol Geriatr; 2010; 51(3):245-9. PubMed ID: 19969381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease.
    Yoshida T; Ha-Kawa S; Yoshimura M; Nobuhara K; Kinoshita T; Sawada S
    Ann Nucl Med; 2007 Jul; 21(5):257-65. PubMed ID: 17634843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
    Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
    Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
    Rogers SL
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
    Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
    Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
    Li DQ; Zhou YP; Yang H
    Int J Med Sci; 2012; 9(3):248-55. PubMed ID: 22606044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease.
    Hegedűs É; Pákáski M; Gosztolya G; Hoffmann I; Kovács I; Kálmán J
    PLoS One; 2024; 19(8):e0308409. PubMed ID: 39163290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
    Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
    Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.